Cover Image
Market Research Report
Product code
1024377

Asia-pacific Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2021-2028

Published: | Inkwood Research | 151 Pages | Delivery time: 2-3 business days

Price

Back to Top
Asia-pacific Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2021-2028
Published: August 23, 2021
Inkwood Research
Content info: 151 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

KEY FINDINGS The Asia-Pacific Alzheimer's disease therapeutics and diagnostics market is estimated to register a CAGR of 5.67% during the forecast period, 2021-2028. The increasing number of age-induced dementia cases is set to propel market growth in the Asia Pacific.

MARKET INSIGHTS

China, South Korea, Japan, India, Vietnam, Indonesia, Australia & New Zealand, Thailand, and the rest of Asia-Pacific are evaluated for the Asia-Pacific Alzheimer's disease therapeutics and diagnostics market growth analysis. As per the United Nations Population Fund 2017 report, in India, the number of dementia cases is projected to reach 1.3 million in 2020 and 1.7 million by 2030. Also, the rising burden of Alzheimer's disease has led to the growing demand for new healthcare technological advancements in the treatment and early diagnosis of dementia. Moreover, the geriatric population is set to increase, which is set to drive market growth. The country is participating in massive collaborative research work for Alzheimer's. At the same time, there is a lack of industry-sponsored research for enhancing the current medications, and improving diagnostic modalities for Alzheimer's and R&D for developing new interventions. India is expected to project a moderate growth during the forecast period, despite considerable efforts at the national level for Alzheimer's.

In Australia, the number of dementia cases is expected to reach 1,076,129 by 2058, according to Dementia Australia. Further, dementia is one of the most significant healthcare challenges in New Zealand, as per Alzheimer.org data. The Australia & New Zealand Alzheimer's disease therapeutics and diagnostics market is consolidated, and the current policies and framework are estimated to fuel the market growth further.

COMPETITIVE INSIGHTS

Some of the distinguished players in the market include, Pfizer Inc, Novartis AG, GE Healthcare, Johnson & Johnson, Eli Lilly & Company, Sun Pharmaceuticals Industries Ltd, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 16805

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING GERIATRIC POPULATION
    • 3.2.2. RISE IN THE PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.2.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
  • 3.3. KEY RESTRAINTS
    • 3.3.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.3.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.3.3. LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. BUYERS POWER
    • 4.1.2. SUPPLIERS POWER
    • 4.1.3. SUBSTITUTION
    • 4.1.4. NEW ENTRANTS
    • 4.1.5. INDUSTRY RIVALRY
  • 4.2. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 4.3. KEY BUYING CRITERIA
  • 4.4. ETYMOLOGY OF ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 4.5. SUPPLY CHAIN ANALYSIS
  • 4.6. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.7. OPPORTUNITY MATRIX
  • 4.8. VENDOR LANDSCAPE
  • 4.9. KEY MARKET TRENDS

5. MARKET BY THERAPEUTICS AND DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. THERAPEUTICS BY DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. THERAPEUTICS BY DISEASE STAGE
      • 5.1.2.1. LATE STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. THERAPEUTICS BY GENERIC AND BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. BLOOD TEST
    • 5.2.7. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. ASIA-PACIFIC
    • 6.1.1. MARKET SIZE & ESTIMATES
    • 6.1.2. KEY GROWTH ENABLERS
    • 6.1.3. KEY CHALLENGES
    • 6.1.4. KEY PLAYERS
    • 6.1.5. COUNTRY ANALYSIS
      • 6.1.5.1. CHINA
      • 6.1.5.2. INDIA
      • 6.1.5.3. JAPAN
      • 6.1.5.4. AUSTRALIA & NEW ZEALAND
      • 6.1.5.5. SOUTH KOREA
      • 6.1.5.6. THAILAND
      • 6.1.5.7. INDONESIA
      • 6.1.5.8. VIETNAM
      • 6.1.5.9. REST OF ASIA-PACIFIC

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIC DEVELOPMENTS
    • 7.1.1. MERGERS & ACQUISITIONS
    • 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 7.1.3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
    • 7.1.4. BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
  • 7.2. COMPANY PROFILES
    • 7.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 7.2.2. AMARANTUS BIOSCIENCE HOLDINGS INC
    • 7.2.3. BAXTER INTERNATIONAL INC
    • 7.2.4. BIOGEN INC
    • 7.2.5. COGNOPTIX INC
    • 7.2.6. EISAI CO LTD
    • 7.2.7. ELI LILLY & COMPANY
    • 7.2.8. F. HOFFMANN-LA ROCHE
    • 7.2.9. GE HEALTHCARE
    • 7.2.10. JOHNSON & JOHNSON
    • 7.2.11. LUPIN LIMITED
    • 7.2.12. MERCK & CO INC
    • 7.2.13. NOVARTIS AG
    • 7.2.14. PFIZER INC
    • 7.2.15. SIEMENS HEALTHINEERS AG
    • 7.2.16. SUN PHARMACEUTICALS INDUSTRIES LTD
    • 7.2.17. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.2.18. ZYDUS CADILA

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS
  • TABLE 2: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 3: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 4: ASIA-PACIFIC THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 5: ASIA-PACIFIC THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 6: ASIA-PACIFIC THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 7: ASIA-PACIFIC THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 8: ASIA-PACIFIC THERAPEUTICS MARKET, BY GENERIC AND BRANDED, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 9: ASIA-PACIFIC THERAPEUTICS MARKET, BY GENERIC AND BRANDED, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 10: ASIA-PACIFIC DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 11: ASIA-PACIFIC DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 12: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 13: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 14: LEADING PLAYERS OPERATING IN THE ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • TABLE 15: LIST OF MERGERS & ACQUISITIONS
  • TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 17: LIST OF PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
  • TABLE 18: LIST OF BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: SUPPLY CHAIN ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: KEY MARKET TRENDS
  • FIGURE 6: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021-2028 ($ MILLION)
  • FIGURE 7: ASIA-PACIFIC THERAPEUTICS MARKET, BY MARKETED DRUGS, 2021-2028 ($ MILLION)
  • FIGURE 8: ASIA-PACIFIC THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2021-2028 ($ MILLION)
  • FIGURE 9: ASIA-PACIFIC THERAPEUTICS MARKET, BY LATE STAGE, 2021-2028 ($ MILLION)
  • FIGURE 10: ASIA-PACIFIC THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE, 2021-2028 ($ MILLION)
  • FIGURE 11: ASIA-PACIFIC THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2021-2028 ($ MILLION)
  • FIGURE 12: ASIA-PACIFIC THERAPEUTICS MARKET, BY BRANDED, 2021-2028 ($ MILLION)
  • FIGURE 13: ASIA-PACIFIC THERAPEUTICS MARKET, BY GENERIC, 2021-2028 ($ MILLION)
  • FIGURE 14: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021-2028 ($ MILLION)
  • FIGURE 15: ASIA-PACIFIC DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2021-2028 ($ MILLION)
  • FIGURE 16: ASIA-PACIFIC DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2021-2028 ($ MILLION)
  • FIGURE 17: ASIA-PACIFIC DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2021-2028 ($ MILLION)
  • FIGURE 18: ASIA-PACIFIC DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2021-2028 ($ MILLION)
  • FIGURE 19: ASIA-PACIFIC DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2021-2028 ($ MILLION)
  • FIGURE 20: ASIA-PACIFIC DIAGNOSTICS MARKET, BY BLOOD TEST, 2021-2028 ($ MILLION)
  • FIGURE 21: ASIA-PACIFIC DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2021-2028 ($ MILLION)
  • FIGURE 22: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 23: CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 24: INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 25: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 26: AUSTRALIA & NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 27: SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 28: THAILAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 29: INDONESIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: VIETNAM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 31: REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)